ClinicalTrials.gg
RecruitingNCT07511205Updated Nov 9, 2026

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

A Phase 1 interventional study of AZD1043 and Placebo in Healthy Participants and Obesity, sponsored by AstraZeneca. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Obesity by AstraZeneca — 8 open to participants now, 12 under way, 5 of them phase 3. Obesity · AstraZeneca.

Planned enrollment
22nd of 50
104 · median 87
Started
2026
with 8 others
Phase 1
24 of 52
3 open now
Primary completion
2027-04
later than 4 of 11 live
Registered
44th of 52
by date

Among the 52 studies in Obesity by AstraZeneca, this one is the 22nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2026, is one of 24 in phase 1, reaches primary completion later than 4 of the 11 other live ones, and was the 44th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 52 studies in Obesity by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Obesity by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

Read the detailed description

This is a phase 1, first time in human (FTiH) randomized, single-blind, placebo-controlled study in healthy male and female participants living with overweight and/or obesity, with female participants being of non-childbearing potential. It consists of 2 parts:

Part A (single ascending doses: SAD): This will consist of Part A1 (Global SAD (GSAD)) with 6 cohorts, Part A2 (Japanese SAD (JSAD)) with 2 cohorts and Part A3 (Chinese SAD (CSAD)) with 1 cohort.

Part B (multiple ascending doses: MAD): This will consist of Part B1 (Global MAD (GMAD)) with 3 cohorts and Part B2 (Japanese MAD (JMAD)) with 1 cohort.

Participants are only allowed to participate in one of the cohorts.

Both Part A and Part B will comprise of:

  • Screening period (up to 5 weeks).
  • Treatment period.
  • Safety follow-up period.
03

Conditions studied

  • Healthy Participants
  • Obesity

Browse trials for

Keywords

  • First time in human
  • Single ascending dose
  • Multiple ascending dose
  • Pharmacokinetics
  • Pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of non- must be confirmed as or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
  • Have a between 25 and 39.9 kg/m2 (Global cohorts [Parts A1 and B1]), or 23 and 39.9 kg/m2 (Japanese [Parts A2 and B2] and Chinese [Part A3] cohorts) inclusive and weigh at least 50 kg.
  • For the Parts A2 and B2, participants should be Japanese (natives of Japan or Japanese Americans), having both parents and 4 grandparents who are Japanese. This includes healthy second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
  • For the Part A3, participants should be Chinese defined as having both parents and 4 grandparents who are ethnically Chinese. This includes second and third generation Chinese whose parents or grandparents are living in a country other than China.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
  • Any clinically important abnormalities in laboratory values, clinical chemistry, hematology, urinalysis results, or vital signs.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity to drugs of a similar class to AZD1043.
  • Has received prescription, non-prescription, or experimental medications for weight loss within 3 months prior to the Screening Visit.
  • History of psychosis or bipolar disorder or major depressive disorder within the past 2 years with the participant being clinically unstable.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Part A1 (Global SAD): Cohort 1 - AZD1043 (Dose 1)

    Participants will receive a single dose of AZD1043 (Dose 1) or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A1 (Global SAD): Cohort 2 - AZD1043 (Dose 2)

    Participants will receive a single dose of AZD1043 (Dose 2) or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A1 (Global SAD): Cohort 3 - AZD1043 (Dose 3)

    Participants will receive a single dose of AZD1043 (Dose 3) or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A1 (Global SAD): Cohort 4 - AZD1043 (Dose 4)

    Participants will receive a single dose of AZD1043 (Dose 4) or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A1 (Global SAD): Cohort 5 - AZD1043 (Dose 5)

    Participants will receive a single dose of AZD1043 (Dose 5) or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A1 (Global SAD): Cohort 6 - AZD1043 (Dose 6)

    Participants will receive a single dose of AZD1043 (Dose 6) or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A2 (Japanese SAD): Cohort 1 - AZD1043 (Dose X)

    Japanese participants will receive a single dose of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A2 (Japanese SAD): Cohort 2 - AZD1043 (Dose Y)

    Japanese participants will receive a single dose of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part A3 (Chinese SAD): Cohort 1 - AZD1043 (Dose Z)

    Chinese participants will receive a single dose of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part B1 (Global MAD): Cohort 1 - AZD1043 (Dose A)

    Participants will receive multiple doses of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part B1 (Global MAD): Cohort 2 - AZD1043 (Dose B)

    Participants will receive multiple doses of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part B1 (Global MAD): Cohort 3 - AZD1043 (Dose C)

    Participants will receive multiple doses of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

  • Experimental
    Part B2 (Japanese MAD): Cohort 1 - AZD1043 (Dose D)

    Japanese participants will receive multiple doses of AZD1043 or placebo.

    Drug: AZD1043 · Other: Placebo

Interventions

  • DrugAZD1043

    Single or multiple doses of AZD1043 will be administered.

  • OtherPlacebo

    Matching placebo to AZD1043 will be administered.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs)

    To assess the safety and tolerability of a single or multiple doses of AZD1043 in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

    Time frame: Part A (SAD): From Day-35 to Day 253; Part B (MAD): From Day 1 to Day 253

Secondary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf) (Part A only)

    To characterize the PK of a single or multiple doses of AZD1043 in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

    Time frame: From Day 1 to Day 253

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the PK of a single or multiple doses of AZD1043 in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

    Time frame: From Day 1 to Day 253

  3. Maximum observed drug concentration (Cmax)

    To characterize the PK of a single or multiple doses of AZD1043 in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.

    Time frame: From Day 1 to Day 253

07

Study locations

2 of 3 sites recruiting
  • Research Site
    Glendale, California 91206, United States
    Recruiting
  • Research Site
    Brooklyn, Maryland 21225, United States
    Recruiting
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
    Not yet recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 12 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 6, 2026
StartActual
Mar 30, 2026
Primary completionEst.
Apr 9, 2027
CompletionEst.
Nov 17, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Recruiting
Oct 13, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 13, 2026
    Research Site is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07511205
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 6, 2026
Start date
Mar 30, 2026
Primary completion
Apr 9, 2027 (estimated)
Completion
Nov 17, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion